Skip to content

Yuxintong showed mixed fitness results versus placebo in stable coronary heart disease

Adding the capsule to conventional care improved a fitness measure and selected quality-of-life scores. Peak oxygen uptake showed no statistically significant advantage over placebo.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Adding Yuxintong to conventional treatment improved anaerobic threshold, a fitness measure based on oxygen uptake during exercise. However, peak oxygen uptake showed no statistically significant advantage over placebo. General health and vitality questionnaire scores improved. These mixed results do not establish a broad improvement in heart health or lasting benefit.

Keep in mind

The abstract does not explain why fewer participants were analyzed than randomized. It provides limited safety details and no results beyond the treatment period, restricting conclusions about longer-term effects.

THE RESULT, WITH CONTEXT

What researchers found

Improvement reported

Anaerobic threshold, a fitness measure

At 12 weeks, Yuxintong plus conventional treatment versus placebo plus the same treatment; the reported improvement was statistically significant.

J Ethnopharmacol, 2026 · Original source ↓

What the trial asked

Researchers tested whether adding Yuxintong capsules to conventional care improved fitness in stable coronary heart disease. The primary outcomes were anaerobic threshold and peak oxygen uptake, so the trial's main question concerned measured fitness.

Other outcomes

General health and vitality questionnaire scores improved with Yuxintong. Other exercise and electrocardiogram outcomes did not differ significantly between groups. Adverse events were described as similar, but detailed safety results were not supplied.

CHECK THE ORIGINAL

The original publication

Efficacy of Yuxintong capsule on cardiorespiratory fitness in patients with stable coronary heart disease: A multicentre, randomized, double-blind, placebo-controlled, parallel-group clinical trial.

Zheng L, Fu C, Song L et al.
J Ethnopharmacol · 2026

PubMed ID
41500352
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.